nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—CYP2D6—breast cancer	0.457	1	CbGaD
Labetalol—CYP2D6—Idarubicin—breast cancer	0.0408	0.414	CbGbCtD
Labetalol—CYP2D6—Vinorelbine—breast cancer	0.0199	0.202	CbGbCtD
Labetalol—CYP2D6—Tamoxifen—breast cancer	0.018	0.183	CbGbCtD
Labetalol—CYP2D6—Vinblastine—breast cancer	0.0123	0.125	CbGbCtD
Labetalol—CYP2D6—Doxorubicin—breast cancer	0.00754	0.0766	CbGbCtD
Labetalol—Dobutamine—COMT—breast cancer	0.000876	0.107	CrCbGaD
Labetalol—Mirabegron—BCHE—breast cancer	0.00072	0.088	CrCbGaD
Labetalol—Benazepril—MTHFR—breast cancer	0.000583	0.0713	CrCbGaD
Labetalol—Salsalate—PTGS1—breast cancer	0.00042	0.0513	CrCbGaD
Labetalol—Ketoprofen—CXCL8—breast cancer	0.000401	0.049	CrCbGaD
Labetalol—Mirabegron—CYP2D6—breast cancer	0.000395	0.0483	CrCbGaD
Labetalol—Fenoprofen—PTGS1—breast cancer	0.000347	0.0424	CrCbGaD
Labetalol—Mirabegron—CYP3A4—breast cancer	0.000339	0.0414	CrCbGaD
Labetalol—Arformoterol—CYP2D6—breast cancer	0.000316	0.0386	CrCbGaD
Labetalol—Formoterol—CYP2D6—breast cancer	0.000316	0.0386	CrCbGaD
Labetalol—Salmeterol—CYP3A4—breast cancer	0.00031	0.0379	CrCbGaD
Labetalol—Mirabegron—ALB—breast cancer	0.000296	0.0361	CrCbGaD
Labetalol—Mirabegron—ABCB1—breast cancer	0.000282	0.0345	CrCbGaD
Labetalol—Salsalate—PTGS2—breast cancer	0.00024	0.0293	CrCbGaD
Labetalol—Isoprenaline—CYP1A1—breast cancer	0.000228	0.0279	CrCbGaD
Labetalol—Flurbiprofen—PTGS1—breast cancer	0.000226	0.0277	CrCbGaD
Labetalol—Tolterodine—CYP2D6—breast cancer	0.000207	0.0254	CrCbGaD
Labetalol—Ketoprofen—PTGS1—breast cancer	0.000205	0.025	CrCbGaD
Labetalol—Fenoprofen—PTGS2—breast cancer	0.000198	0.0242	CrCbGaD
Labetalol—Tolterodine—CYP3A4—breast cancer	0.000178	0.0218	CrCbGaD
Labetalol—Fenoprofen—ALB—breast cancer	0.000177	0.0216	CrCbGaD
Labetalol—Propafenone—CYP2D6—breast cancer	0.000176	0.0216	CrCbGaD
Labetalol—Propafenone—CYP3A4—breast cancer	0.000151	0.0185	CrCbGaD
Labetalol—Headache—Thiotepa—breast cancer	0.000139	0.00038	CcSEcCtD
Labetalol—Somnolence—Paclitaxel—breast cancer	0.000139	0.00038	CcSEcCtD
Labetalol—Palpitations—Capecitabine—breast cancer	0.000139	0.00038	CcSEcCtD
Labetalol—Loss of consciousness—Capecitabine—breast cancer	0.000138	0.000378	CcSEcCtD
Labetalol—Nausea—Vinorelbine—breast cancer	0.000138	0.000378	CcSEcCtD
Labetalol—Dyspepsia—Paclitaxel—breast cancer	0.000137	0.000376	CcSEcCtD
Labetalol—Asthenia—Irinotecan—breast cancer	0.000137	0.000376	CcSEcCtD
Labetalol—Asthenia—Mitoxantrone—breast cancer	0.000137	0.000376	CcSEcCtD
Labetalol—Jaundice—Epirubicin—breast cancer	0.000136	0.000374	CcSEcCtD
Labetalol—Dysuria—Doxorubicin—breast cancer	0.000136	0.000372	CcSEcCtD
Labetalol—Hypertension—Capecitabine—breast cancer	0.000135	0.000371	CcSEcCtD
Labetalol—Hypersensitivity—Fluorouracil—breast cancer	0.000135	0.00037	CcSEcCtD
Labetalol—Fatigue—Paclitaxel—breast cancer	0.000134	0.000369	CcSEcCtD
Labetalol—Hepatitis—Methotrexate—breast cancer	0.000134	0.000368	CcSEcCtD
Labetalol—Sweating—Epirubicin—breast cancer	0.000134	0.000367	CcSEcCtD
Labetalol—Asthenia—Gemcitabine—breast cancer	0.000134	0.000366	CcSEcCtD
Labetalol—Pain—Paclitaxel—breast cancer	0.000133	0.000366	CcSEcCtD
Labetalol—Constipation—Paclitaxel—breast cancer	0.000133	0.000366	CcSEcCtD
Labetalol—Confusional state—Docetaxel—breast cancer	0.000133	0.000365	CcSEcCtD
Labetalol—Anaphylactic shock—Docetaxel—breast cancer	0.000132	0.000362	CcSEcCtD
Labetalol—Oedema—Docetaxel—breast cancer	0.000132	0.000362	CcSEcCtD
Labetalol—Discomfort—Capecitabine—breast cancer	0.000132	0.000362	CcSEcCtD
Labetalol—Epistaxis—Epirubicin—breast cancer	0.000132	0.000361	CcSEcCtD
Labetalol—Pruritus—Gemcitabine—breast cancer	0.000132	0.000361	CcSEcCtD
Labetalol—Nausea—Thiotepa—breast cancer	0.000132	0.000361	CcSEcCtD
Labetalol—Diarrhoea—Irinotecan—breast cancer	0.000131	0.000359	CcSEcCtD
Labetalol—Diarrhoea—Mitoxantrone—breast cancer	0.000131	0.000359	CcSEcCtD
Labetalol—Agranulocytosis—Epirubicin—breast cancer	0.00013	0.000358	CcSEcCtD
Labetalol—Shock—Docetaxel—breast cancer	0.00013	0.000356	CcSEcCtD
Labetalol—Pruritus—Fluorouracil—breast cancer	0.00013	0.000355	CcSEcCtD
Labetalol—Drowsiness—Doxorubicin—breast cancer	0.000129	0.000355	CcSEcCtD
Labetalol—Flurbiprofen—PTGS2—breast cancer	0.000129	0.0158	CrCbGaD
Labetalol—Visual impairment—Methotrexate—breast cancer	0.000129	0.000354	CcSEcCtD
Labetalol—Confusional state—Capecitabine—breast cancer	0.000129	0.000354	CcSEcCtD
Labetalol—Feeling abnormal—Paclitaxel—breast cancer	0.000129	0.000352	CcSEcCtD
Labetalol—Oedema—Capecitabine—breast cancer	0.000128	0.000351	CcSEcCtD
Labetalol—Bradycardia—Epirubicin—breast cancer	0.000128	0.00035	CcSEcCtD
Labetalol—Gastrointestinal pain—Paclitaxel—breast cancer	0.000128	0.00035	CcSEcCtD
Labetalol—Diarrhoea—Gemcitabine—breast cancer	0.000127	0.000349	CcSEcCtD
Labetalol—Dizziness—Irinotecan—breast cancer	0.000126	0.000347	CcSEcCtD
Labetalol—Jaundice—Doxorubicin—breast cancer	0.000126	0.000346	CcSEcCtD
Labetalol—Propafenone—ABCB1—breast cancer	0.000126	0.0154	CrCbGaD
Labetalol—Shock—Capecitabine—breast cancer	0.000126	0.000345	CcSEcCtD
Labetalol—Hepatitis—Epirubicin—breast cancer	0.000126	0.000344	CcSEcCtD
Labetalol—Diarrhoea—Fluorouracil—breast cancer	0.000125	0.000343	CcSEcCtD
Labetalol—Hypoaesthesia—Epirubicin—breast cancer	0.000125	0.000342	CcSEcCtD
Labetalol—Sweating—Doxorubicin—breast cancer	0.000124	0.00034	CcSEcCtD
Labetalol—Urticaria—Paclitaxel—breast cancer	0.000124	0.00034	CcSEcCtD
Labetalol—Hyperhidrosis—Capecitabine—breast cancer	0.000124	0.000339	CcSEcCtD
Labetalol—Oedema peripheral—Epirubicin—breast cancer	0.000124	0.000339	CcSEcCtD
Labetalol—Hypotension—Docetaxel—breast cancer	0.000124	0.000339	CcSEcCtD
Labetalol—Abdominal pain—Paclitaxel—breast cancer	0.000123	0.000338	CcSEcCtD
Labetalol—Body temperature increased—Paclitaxel—breast cancer	0.000123	0.000338	CcSEcCtD
Labetalol—Epistaxis—Doxorubicin—breast cancer	0.000122	0.000334	CcSEcCtD
Labetalol—Vomiting—Irinotecan—breast cancer	0.000122	0.000333	CcSEcCtD
Labetalol—Vomiting—Mitoxantrone—breast cancer	0.000122	0.000333	CcSEcCtD
Labetalol—Dizziness—Fluorouracil—breast cancer	0.000121	0.000332	CcSEcCtD
Labetalol—Visual impairment—Epirubicin—breast cancer	0.000121	0.000331	CcSEcCtD
Labetalol—Agranulocytosis—Doxorubicin—breast cancer	0.000121	0.000331	CcSEcCtD
Labetalol—Rash—Irinotecan—breast cancer	0.000121	0.00033	CcSEcCtD
Labetalol—Rash—Mitoxantrone—breast cancer	0.000121	0.00033	CcSEcCtD
Labetalol—Dermatitis—Mitoxantrone—breast cancer	0.00012	0.00033	CcSEcCtD
Labetalol—Dermatitis—Irinotecan—breast cancer	0.00012	0.00033	CcSEcCtD
Labetalol—Headache—Mitoxantrone—breast cancer	0.00012	0.000328	CcSEcCtD
Labetalol—Headache—Irinotecan—breast cancer	0.00012	0.000328	CcSEcCtD
Labetalol—Hypotension—Capecitabine—breast cancer	0.00012	0.000328	CcSEcCtD
Labetalol—Paraesthesia—Docetaxel—breast cancer	0.000119	0.000325	CcSEcCtD
Labetalol—Alopecia—Methotrexate—breast cancer	0.000119	0.000325	CcSEcCtD
Labetalol—Vomiting—Gemcitabine—breast cancer	0.000118	0.000325	CcSEcCtD
Labetalol—Bradycardia—Doxorubicin—breast cancer	0.000118	0.000324	CcSEcCtD
Labetalol—Dyspnoea—Docetaxel—breast cancer	0.000118	0.000323	CcSEcCtD
Labetalol—Somnolence—Docetaxel—breast cancer	0.000118	0.000322	CcSEcCtD
Labetalol—Mental disorder—Methotrexate—breast cancer	0.000117	0.000322	CcSEcCtD
Labetalol—Rash—Gemcitabine—breast cancer	0.000117	0.000322	CcSEcCtD
Labetalol—Dermatitis—Gemcitabine—breast cancer	0.000117	0.000322	CcSEcCtD
Labetalol—Ketoprofen—PTGS2—breast cancer	0.000117	0.0143	CrCbGaD
Labetalol—Erythema—Methotrexate—breast cancer	0.000117	0.00032	CcSEcCtD
Labetalol—Headache—Gemcitabine—breast cancer	0.000117	0.00032	CcSEcCtD
Labetalol—Flushing—Epirubicin—breast cancer	0.000116	0.000319	CcSEcCtD
Labetalol—Vomiting—Fluorouracil—breast cancer	0.000116	0.000319	CcSEcCtD
Labetalol—Dyspepsia—Docetaxel—breast cancer	0.000116	0.000319	CcSEcCtD
Labetalol—Hepatitis—Doxorubicin—breast cancer	0.000116	0.000318	CcSEcCtD
Labetalol—Hypoaesthesia—Doxorubicin—breast cancer	0.000116	0.000317	CcSEcCtD
Labetalol—Rash—Fluorouracil—breast cancer	0.000115	0.000317	CcSEcCtD
Labetalol—Dermatitis—Fluorouracil—breast cancer	0.000115	0.000316	CcSEcCtD
Labetalol—Flurbiprofen—ALB—breast cancer	0.000115	0.0141	CrCbGaD
Labetalol—Paraesthesia—Capecitabine—breast cancer	0.000115	0.000315	CcSEcCtD
Labetalol—Hypersensitivity—Paclitaxel—breast cancer	0.000115	0.000315	CcSEcCtD
Labetalol—Headache—Fluorouracil—breast cancer	0.000115	0.000314	CcSEcCtD
Labetalol—Oedema peripheral—Doxorubicin—breast cancer	0.000114	0.000314	CcSEcCtD
Labetalol—Dyspnoea—Capecitabine—breast cancer	0.000114	0.000313	CcSEcCtD
Labetalol—Fatigue—Docetaxel—breast cancer	0.000114	0.000312	CcSEcCtD
Labetalol—Nausea—Mitoxantrone—breast cancer	0.000114	0.000311	CcSEcCtD
Labetalol—Nausea—Irinotecan—breast cancer	0.000114	0.000311	CcSEcCtD
Labetalol—Pain—Docetaxel—breast cancer	0.000113	0.00031	CcSEcCtD
Labetalol—Constipation—Docetaxel—breast cancer	0.000113	0.00031	CcSEcCtD
Labetalol—Dyspepsia—Capecitabine—breast cancer	0.000113	0.000309	CcSEcCtD
Labetalol—Visual impairment—Doxorubicin—breast cancer	0.000112	0.000307	CcSEcCtD
Labetalol—Asthenia—Paclitaxel—breast cancer	0.000112	0.000307	CcSEcCtD
Labetalol—Alopecia—Epirubicin—breast cancer	0.000111	0.000304	CcSEcCtD
Labetalol—Nausea—Gemcitabine—breast cancer	0.000111	0.000303	CcSEcCtD
Labetalol—Fatigue—Capecitabine—breast cancer	0.00011	0.000302	CcSEcCtD
Labetalol—Pruritus—Paclitaxel—breast cancer	0.00011	0.000302	CcSEcCtD
Labetalol—Vision blurred—Methotrexate—breast cancer	0.00011	0.000302	CcSEcCtD
Labetalol—Mental disorder—Epirubicin—breast cancer	0.00011	0.000301	CcSEcCtD
Labetalol—Constipation—Capecitabine—breast cancer	0.000109	0.0003	CcSEcCtD
Labetalol—Pain—Capecitabine—breast cancer	0.000109	0.0003	CcSEcCtD
Labetalol—Erythema—Epirubicin—breast cancer	0.000109	0.000299	CcSEcCtD
Labetalol—Feeling abnormal—Docetaxel—breast cancer	0.000109	0.000299	CcSEcCtD
Labetalol—Nausea—Fluorouracil—breast cancer	0.000109	0.000298	CcSEcCtD
Labetalol—Ill-defined disorder—Methotrexate—breast cancer	0.000108	0.000297	CcSEcCtD
Labetalol—Gastrointestinal pain—Docetaxel—breast cancer	0.000108	0.000296	CcSEcCtD
Labetalol—Flushing—Doxorubicin—breast cancer	0.000108	0.000295	CcSEcCtD
Labetalol—Diarrhoea—Paclitaxel—breast cancer	0.000107	0.000292	CcSEcCtD
Labetalol—Feeling abnormal—Capecitabine—breast cancer	0.000105	0.000289	CcSEcCtD
Labetalol—Malaise—Methotrexate—breast cancer	0.000105	0.000289	CcSEcCtD
Labetalol—Muscle spasms—Epirubicin—breast cancer	0.000105	0.000288	CcSEcCtD
Labetalol—Vertigo—Methotrexate—breast cancer	0.000105	0.000287	CcSEcCtD
Labetalol—Gastrointestinal pain—Capecitabine—breast cancer	0.000105	0.000287	CcSEcCtD
Labetalol—Abdominal pain—Docetaxel—breast cancer	0.000105	0.000286	CcSEcCtD
Labetalol—Body temperature increased—Docetaxel—breast cancer	0.000105	0.000286	CcSEcCtD
Labetalol—Ketoprofen—ALB—breast cancer	0.000104	0.0127	CrCbGaD
Labetalol—Dizziness—Paclitaxel—breast cancer	0.000103	0.000283	CcSEcCtD
Labetalol—Vision blurred—Epirubicin—breast cancer	0.000103	0.000282	CcSEcCtD
Labetalol—Alopecia—Doxorubicin—breast cancer	0.000103	0.000281	CcSEcCtD
Labetalol—Mental disorder—Doxorubicin—breast cancer	0.000102	0.000279	CcSEcCtD
Labetalol—Urticaria—Capecitabine—breast cancer	0.000102	0.000279	CcSEcCtD
Labetalol—Ill-defined disorder—Epirubicin—breast cancer	0.000101	0.000278	CcSEcCtD
Labetalol—Abdominal pain—Capecitabine—breast cancer	0.000101	0.000277	CcSEcCtD
Labetalol—Body temperature increased—Capecitabine—breast cancer	0.000101	0.000277	CcSEcCtD
Labetalol—Erythema—Doxorubicin—breast cancer	0.000101	0.000277	CcSEcCtD
Labetalol—Vomiting—Paclitaxel—breast cancer	9.92e-05	0.000272	CcSEcCtD
Labetalol—Malaise—Epirubicin—breast cancer	9.85e-05	0.00027	CcSEcCtD
Labetalol—Rash—Paclitaxel—breast cancer	9.83e-05	0.00027	CcSEcCtD
Labetalol—Dermatitis—Paclitaxel—breast cancer	9.83e-05	0.000269	CcSEcCtD
Labetalol—Discomfort—Methotrexate—breast cancer	9.82e-05	0.000269	CcSEcCtD
Labetalol—Vertigo—Epirubicin—breast cancer	9.82e-05	0.000269	CcSEcCtD
Labetalol—Syncope—Epirubicin—breast cancer	9.8e-05	0.000269	CcSEcCtD
Labetalol—Headache—Paclitaxel—breast cancer	9.77e-05	0.000268	CcSEcCtD
Labetalol—Hypersensitivity—Docetaxel—breast cancer	9.74e-05	0.000267	CcSEcCtD
Labetalol—Muscle spasms—Doxorubicin—breast cancer	9.72e-05	0.000266	CcSEcCtD
Labetalol—Palpitations—Epirubicin—breast cancer	9.66e-05	0.000265	CcSEcCtD
Labetalol—Confusional state—Methotrexate—breast cancer	9.61e-05	0.000263	CcSEcCtD
Labetalol—Loss of consciousness—Epirubicin—breast cancer	9.6e-05	0.000263	CcSEcCtD
Labetalol—Anaphylactic shock—Methotrexate—breast cancer	9.53e-05	0.000261	CcSEcCtD
Labetalol—Vision blurred—Doxorubicin—breast cancer	9.53e-05	0.000261	CcSEcCtD
Labetalol—Asthenia—Docetaxel—breast cancer	9.49e-05	0.00026	CcSEcCtD
Labetalol—Hypertension—Epirubicin—breast cancer	9.43e-05	0.000259	CcSEcCtD
Labetalol—Hypersensitivity—Capecitabine—breast cancer	9.43e-05	0.000258	CcSEcCtD
Labetalol—Ill-defined disorder—Doxorubicin—breast cancer	9.38e-05	0.000257	CcSEcCtD
Labetalol—Pruritus—Docetaxel—breast cancer	9.35e-05	0.000256	CcSEcCtD
Labetalol—Nausea—Paclitaxel—breast cancer	9.26e-05	0.000254	CcSEcCtD
Labetalol—Hyperhidrosis—Methotrexate—breast cancer	9.21e-05	0.000252	CcSEcCtD
Labetalol—Discomfort—Epirubicin—breast cancer	9.19e-05	0.000252	CcSEcCtD
Labetalol—Asthenia—Capecitabine—breast cancer	9.18e-05	0.000252	CcSEcCtD
Labetalol—Malaise—Doxorubicin—breast cancer	9.12e-05	0.00025	CcSEcCtD
Labetalol—Vertigo—Doxorubicin—breast cancer	9.08e-05	0.000249	CcSEcCtD
Labetalol—Syncope—Doxorubicin—breast cancer	9.07e-05	0.000248	CcSEcCtD
Labetalol—Pruritus—Capecitabine—breast cancer	9.06e-05	0.000248	CcSEcCtD
Labetalol—Diarrhoea—Docetaxel—breast cancer	9.05e-05	0.000248	CcSEcCtD
Labetalol—Confusional state—Epirubicin—breast cancer	8.99e-05	0.000246	CcSEcCtD
Labetalol—Palpitations—Doxorubicin—breast cancer	8.93e-05	0.000245	CcSEcCtD
Labetalol—Anaphylactic shock—Epirubicin—breast cancer	8.92e-05	0.000244	CcSEcCtD
Labetalol—Oedema—Epirubicin—breast cancer	8.92e-05	0.000244	CcSEcCtD
Labetalol—Hypotension—Methotrexate—breast cancer	8.9e-05	0.000244	CcSEcCtD
Labetalol—Loss of consciousness—Doxorubicin—breast cancer	8.89e-05	0.000244	CcSEcCtD
Labetalol—Shock—Epirubicin—breast cancer	8.77e-05	0.00024	CcSEcCtD
Labetalol—Diarrhoea—Capecitabine—breast cancer	8.76e-05	0.00024	CcSEcCtD
Labetalol—Dizziness—Docetaxel—breast cancer	8.74e-05	0.00024	CcSEcCtD
Labetalol—Hypertension—Doxorubicin—breast cancer	8.73e-05	0.000239	CcSEcCtD
Labetalol—Hyperhidrosis—Epirubicin—breast cancer	8.62e-05	0.000236	CcSEcCtD
Labetalol—Paraesthesia—Methotrexate—breast cancer	8.56e-05	0.000234	CcSEcCtD
Labetalol—Discomfort—Doxorubicin—breast cancer	8.5e-05	0.000233	CcSEcCtD
Labetalol—Dyspnoea—Methotrexate—breast cancer	8.49e-05	0.000233	CcSEcCtD
Labetalol—Somnolence—Methotrexate—breast cancer	8.47e-05	0.000232	CcSEcCtD
Labetalol—Dizziness—Capecitabine—breast cancer	8.46e-05	0.000232	CcSEcCtD
Labetalol—Vomiting—Docetaxel—breast cancer	8.41e-05	0.00023	CcSEcCtD
Labetalol—Dyspepsia—Methotrexate—breast cancer	8.39e-05	0.00023	CcSEcCtD
Labetalol—Rash—Docetaxel—breast cancer	8.34e-05	0.000228	CcSEcCtD
Labetalol—Hypotension—Epirubicin—breast cancer	8.33e-05	0.000228	CcSEcCtD
Labetalol—Dermatitis—Docetaxel—breast cancer	8.33e-05	0.000228	CcSEcCtD
Labetalol—Confusional state—Doxorubicin—breast cancer	8.32e-05	0.000228	CcSEcCtD
Labetalol—Headache—Docetaxel—breast cancer	8.28e-05	0.000227	CcSEcCtD
Labetalol—Oedema—Doxorubicin—breast cancer	8.25e-05	0.000226	CcSEcCtD
Labetalol—Anaphylactic shock—Doxorubicin—breast cancer	8.25e-05	0.000226	CcSEcCtD
Labetalol—Fatigue—Methotrexate—breast cancer	8.21e-05	0.000225	CcSEcCtD
Labetalol—Pain—Methotrexate—breast cancer	8.15e-05	0.000223	CcSEcCtD
Labetalol—Vomiting—Capecitabine—breast cancer	8.14e-05	0.000223	CcSEcCtD
Labetalol—Shock—Doxorubicin—breast cancer	8.12e-05	0.000222	CcSEcCtD
Labetalol—Rash—Capecitabine—breast cancer	8.07e-05	0.000221	CcSEcCtD
Labetalol—Dermatitis—Capecitabine—breast cancer	8.06e-05	0.000221	CcSEcCtD
Labetalol—Headache—Capecitabine—breast cancer	8.02e-05	0.00022	CcSEcCtD
Labetalol—Paraesthesia—Epirubicin—breast cancer	8.01e-05	0.000219	CcSEcCtD
Labetalol—Hyperhidrosis—Doxorubicin—breast cancer	7.98e-05	0.000219	CcSEcCtD
Labetalol—Dyspnoea—Epirubicin—breast cancer	7.95e-05	0.000218	CcSEcCtD
Labetalol—Somnolence—Epirubicin—breast cancer	7.93e-05	0.000217	CcSEcCtD
Labetalol—Nausea—Docetaxel—breast cancer	7.85e-05	0.000215	CcSEcCtD
Labetalol—Feeling abnormal—Methotrexate—breast cancer	7.85e-05	0.000215	CcSEcCtD
Labetalol—Dyspepsia—Epirubicin—breast cancer	7.85e-05	0.000215	CcSEcCtD
Labetalol—Gastrointestinal pain—Methotrexate—breast cancer	7.79e-05	0.000214	CcSEcCtD
Labetalol—Hypotension—Doxorubicin—breast cancer	7.71e-05	0.000211	CcSEcCtD
Labetalol—Fatigue—Epirubicin—breast cancer	7.69e-05	0.000211	CcSEcCtD
Labetalol—Pain—Epirubicin—breast cancer	7.63e-05	0.000209	CcSEcCtD
Labetalol—Constipation—Epirubicin—breast cancer	7.63e-05	0.000209	CcSEcCtD
Labetalol—Nausea—Capecitabine—breast cancer	7.6e-05	0.000208	CcSEcCtD
Labetalol—Urticaria—Methotrexate—breast cancer	7.57e-05	0.000207	CcSEcCtD
Labetalol—Body temperature increased—Methotrexate—breast cancer	7.53e-05	0.000206	CcSEcCtD
Labetalol—Abdominal pain—Methotrexate—breast cancer	7.53e-05	0.000206	CcSEcCtD
Labetalol—Paraesthesia—Doxorubicin—breast cancer	7.41e-05	0.000203	CcSEcCtD
Labetalol—Dyspnoea—Doxorubicin—breast cancer	7.36e-05	0.000202	CcSEcCtD
Labetalol—Feeling abnormal—Epirubicin—breast cancer	7.35e-05	0.000201	CcSEcCtD
Labetalol—Somnolence—Doxorubicin—breast cancer	7.33e-05	0.000201	CcSEcCtD
Labetalol—Gastrointestinal pain—Epirubicin—breast cancer	7.29e-05	0.0002	CcSEcCtD
Labetalol—Dyspepsia—Doxorubicin—breast cancer	7.26e-05	0.000199	CcSEcCtD
Labetalol—Fatigue—Doxorubicin—breast cancer	7.11e-05	0.000195	CcSEcCtD
Labetalol—Urticaria—Epirubicin—breast cancer	7.08e-05	0.000194	CcSEcCtD
Labetalol—Pain—Doxorubicin—breast cancer	7.06e-05	0.000193	CcSEcCtD
Labetalol—Constipation—Doxorubicin—breast cancer	7.06e-05	0.000193	CcSEcCtD
Labetalol—Body temperature increased—Epirubicin—breast cancer	7.05e-05	0.000193	CcSEcCtD
Labetalol—Abdominal pain—Epirubicin—breast cancer	7.05e-05	0.000193	CcSEcCtD
Labetalol—Hypersensitivity—Methotrexate—breast cancer	7.02e-05	0.000192	CcSEcCtD
Labetalol—Asthenia—Methotrexate—breast cancer	6.84e-05	0.000187	CcSEcCtD
Labetalol—Feeling abnormal—Doxorubicin—breast cancer	6.8e-05	0.000186	CcSEcCtD
Labetalol—Gastrointestinal pain—Doxorubicin—breast cancer	6.75e-05	0.000185	CcSEcCtD
Labetalol—Pruritus—Methotrexate—breast cancer	6.74e-05	0.000185	CcSEcCtD
Labetalol—Hypersensitivity—Epirubicin—breast cancer	6.57e-05	0.00018	CcSEcCtD
Labetalol—Urticaria—Doxorubicin—breast cancer	6.55e-05	0.00018	CcSEcCtD
Labetalol—Abdominal pain—Doxorubicin—breast cancer	6.52e-05	0.000179	CcSEcCtD
Labetalol—Body temperature increased—Doxorubicin—breast cancer	6.52e-05	0.000179	CcSEcCtD
Labetalol—Diarrhoea—Methotrexate—breast cancer	6.52e-05	0.000179	CcSEcCtD
Labetalol—Asthenia—Epirubicin—breast cancer	6.4e-05	0.000175	CcSEcCtD
Labetalol—Pruritus—Epirubicin—breast cancer	6.31e-05	0.000173	CcSEcCtD
Labetalol—Dizziness—Methotrexate—breast cancer	6.3e-05	0.000173	CcSEcCtD
Labetalol—Diarrhoea—Epirubicin—breast cancer	6.1e-05	0.000167	CcSEcCtD
Labetalol—Hypersensitivity—Doxorubicin—breast cancer	6.08e-05	0.000167	CcSEcCtD
Labetalol—Vomiting—Methotrexate—breast cancer	6.06e-05	0.000166	CcSEcCtD
Labetalol—Rash—Methotrexate—breast cancer	6.01e-05	0.000165	CcSEcCtD
Labetalol—Dermatitis—Methotrexate—breast cancer	6e-05	0.000165	CcSEcCtD
Labetalol—Headache—Methotrexate—breast cancer	5.97e-05	0.000164	CcSEcCtD
Labetalol—Asthenia—Doxorubicin—breast cancer	5.92e-05	0.000162	CcSEcCtD
Labetalol—Dizziness—Epirubicin—breast cancer	5.9e-05	0.000162	CcSEcCtD
Labetalol—Pruritus—Doxorubicin—breast cancer	5.84e-05	0.00016	CcSEcCtD
Labetalol—Vomiting—Epirubicin—breast cancer	5.67e-05	0.000155	CcSEcCtD
Labetalol—Nausea—Methotrexate—breast cancer	5.66e-05	0.000155	CcSEcCtD
Labetalol—Diarrhoea—Doxorubicin—breast cancer	5.65e-05	0.000155	CcSEcCtD
Labetalol—Rash—Epirubicin—breast cancer	5.62e-05	0.000154	CcSEcCtD
Labetalol—Dermatitis—Epirubicin—breast cancer	5.62e-05	0.000154	CcSEcCtD
Labetalol—Headache—Epirubicin—breast cancer	5.59e-05	0.000153	CcSEcCtD
Labetalol—Dizziness—Doxorubicin—breast cancer	5.46e-05	0.00015	CcSEcCtD
Labetalol—Nausea—Epirubicin—breast cancer	5.3e-05	0.000145	CcSEcCtD
Labetalol—Vomiting—Doxorubicin—breast cancer	5.25e-05	0.000144	CcSEcCtD
Labetalol—Rash—Doxorubicin—breast cancer	5.2e-05	0.000143	CcSEcCtD
Labetalol—Dermatitis—Doxorubicin—breast cancer	5.2e-05	0.000142	CcSEcCtD
Labetalol—Headache—Doxorubicin—breast cancer	5.17e-05	0.000142	CcSEcCtD
Labetalol—Nausea—Doxorubicin—breast cancer	4.9e-05	0.000134	CcSEcCtD
Labetalol—ADRB1—Signaling Pathways—STAT5A—breast cancer	1.58e-05	0.000221	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MMP3—breast cancer	1.58e-05	0.000221	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3CB—breast cancer	1.57e-05	0.00022	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ITPR1—breast cancer	1.55e-05	0.000217	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ERBB4—breast cancer	1.54e-05	0.000216	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—STAT5A—breast cancer	1.54e-05	0.000216	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MMP3—breast cancer	1.54e-05	0.000216	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—DPYD—breast cancer	1.54e-05	0.000216	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MED12—breast cancer	1.54e-05	0.000216	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NOS3—breast cancer	1.54e-05	0.000215	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3CB—breast cancer	1.54e-05	0.000215	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SMAD4—breast cancer	1.53e-05	0.000214	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALDOA—breast cancer	1.52e-05	0.000212	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IGF1R—breast cancer	1.52e-05	0.000212	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CXCL8—breast cancer	1.51e-05	0.000211	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SMAD4—breast cancer	1.49e-05	0.000209	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HES1—breast cancer	1.49e-05	0.000209	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IGF1R—breast cancer	1.48e-05	0.000208	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NCOR1—breast cancer	1.48e-05	0.000207	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PLA2G4A—breast cancer	1.48e-05	0.000207	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CXCL8—breast cancer	1.48e-05	0.000207	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOA3—breast cancer	1.47e-05	0.000206	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PIK3CA—breast cancer	1.47e-05	0.000205	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CSF2—breast cancer	1.47e-05	0.000205	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGF1—breast cancer	1.47e-05	0.000205	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC2A2—breast cancer	1.46e-05	0.000205	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—RAF1—breast cancer	1.46e-05	0.000205	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MDM2—breast cancer	1.46e-05	0.000204	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HES1—breast cancer	1.46e-05	0.000204	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—RAF1—breast cancer	1.46e-05	0.000204	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NRG1—breast cancer	1.45e-05	0.000204	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NCOR1—breast cancer	1.45e-05	0.000203	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PLA2G4A—breast cancer	1.45e-05	0.000203	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—RELA—breast cancer	1.45e-05	0.000203	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—H2AFX—breast cancer	1.44e-05	0.000202	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—IL2—breast cancer	1.44e-05	0.000202	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ERBB2—breast cancer	1.44e-05	0.000201	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—E2F1—breast cancer	1.43e-05	0.000201	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGF1—breast cancer	1.43e-05	0.000201	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CSF2—breast cancer	1.43e-05	0.000201	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ABCG2—breast cancer	1.43e-05	0.000201	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MTR—breast cancer	1.43e-05	0.000201	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CPT1A—breast cancer	1.43e-05	0.000201	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—RAF1—breast cancer	1.43e-05	0.0002	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CB—breast cancer	1.43e-05	0.0002	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NRG1—breast cancer	1.42e-05	0.000199	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CB—breast cancer	1.42e-05	0.000199	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MTOR—breast cancer	1.42e-05	0.000199	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—H2AFX—breast cancer	1.41e-05	0.000198	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—IL2—breast cancer	1.41e-05	0.000198	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HPGDS—breast cancer	1.41e-05	0.000197	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—E2F1—breast cancer	1.4e-05	0.000196	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HBA1—breast cancer	1.4e-05	0.000195	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CB—breast cancer	1.4e-05	0.000195	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SPP1—breast cancer	1.38e-05	0.000193	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CXCL8—breast cancer	1.37e-05	0.000192	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CXCL8—breast cancer	1.37e-05	0.000191	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ACHE—breast cancer	1.36e-05	0.000191	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTT1—breast cancer	1.36e-05	0.000191	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ERBB3—breast cancer	1.36e-05	0.000191	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGFR2—breast cancer	1.36e-05	0.00019	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—HRAS—breast cancer	1.36e-05	0.00019	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SPP1—breast cancer	1.35e-05	0.000189	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CXCL8—breast cancer	1.34e-05	0.000188	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CDKN1B—breast cancer	1.33e-05	0.000187	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ERBB3—breast cancer	1.33e-05	0.000187	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGFR2—breast cancer	1.33e-05	0.000186	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—AKT1—breast cancer	1.32e-05	0.000185	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL2—breast cancer	1.31e-05	0.000183	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CASP3—breast cancer	1.31e-05	0.000183	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TERT—breast cancer	1.31e-05	0.000183	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL2—breast cancer	1.3e-05	0.000183	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—IL6—breast cancer	1.3e-05	0.000182	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP17A1—breast cancer	1.29e-05	0.000181	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL2—breast cancer	1.28e-05	0.000179	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TERT—breast cancer	1.28e-05	0.000179	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTGS1—breast cancer	1.28e-05	0.000179	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ENO1—breast cancer	1.28e-05	0.000179	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CCND1—breast cancer	1.27e-05	0.000178	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—JUN—breast cancer	1.27e-05	0.000178	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGFR1—breast cancer	1.27e-05	0.000177	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CTNNB1—breast cancer	1.26e-05	0.000176	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HIF1A—breast cancer	1.25e-05	0.000175	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGFR1—breast cancer	1.24e-05	0.000174	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MMP9—breast cancer	1.23e-05	0.000173	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CDKN1A—breast cancer	1.23e-05	0.000172	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOA2—breast cancer	1.23e-05	0.000172	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PTEN—breast cancer	1.23e-05	0.000172	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HIF1A—breast cancer	1.22e-05	0.000171	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LEP—breast cancer	1.22e-05	0.000171	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CAV1—breast cancer	1.21e-05	0.000169	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MAPK8—breast cancer	1.2e-05	0.000168	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—AKT1—breast cancer	1.2e-05	0.000168	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KDR—breast cancer	1.19e-05	0.000167	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LEP—breast cancer	1.19e-05	0.000167	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—FASN—breast cancer	1.19e-05	0.000167	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—BCHE—breast cancer	1.19e-05	0.000166	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CAV1—breast cancer	1.18e-05	0.000165	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC5A5—breast cancer	1.17e-05	0.000164	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KDR—breast cancer	1.17e-05	0.000164	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ESR1—breast cancer	1.16e-05	0.000163	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FN1—breast cancer	1.15e-05	0.000161	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ESR1—breast cancer	1.14e-05	0.000159	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SRC—breast cancer	1.14e-05	0.000159	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NFKBIA—breast cancer	1.14e-05	0.000159	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NQO1—breast cancer	1.13e-05	0.000159	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC2A1—breast cancer	1.13e-05	0.000159	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOTCH1—breast cancer	1.13e-05	0.000157	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FN1—breast cancer	1.12e-05	0.000157	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NFKBIA—breast cancer	1.11e-05	0.000156	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—VEGFA—breast cancer	1.11e-05	0.000155	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP3A4—breast cancer	1.1e-05	0.000155	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOTCH1—breast cancer	1.1e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KIT—breast cancer	1.1e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CG—breast cancer	1.1e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—APC—breast cancer	1.1e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—STAT3—breast cancer	1.1e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EGF—breast cancer	1.09e-05	0.000152	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP1B1—breast cancer	1.09e-05	0.000152	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CG—breast cancer	1.08e-05	0.000151	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—APC—breast cancer	1.08e-05	0.000151	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KIT—breast cancer	1.08e-05	0.000151	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HSP90AA1—breast cancer	1.07e-05	0.000149	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EGF—breast cancer	1.06e-05	0.000149	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—MAPK3—breast cancer	1.05e-05	0.000147	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MAPK3—breast cancer	1.05e-05	0.000147	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOA1—breast cancer	1.04e-05	0.000145	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—BRAF—breast cancer	1.03e-05	0.000145	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—MAPK3—breast cancer	1.03e-05	0.000144	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP19A1—breast cancer	1.02e-05	0.000143	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—STK11—breast cancer	1.02e-05	0.000143	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MYC—breast cancer	1.02e-05	0.000143	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TGFB1—breast cancer	1.02e-05	0.000142	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—BRAF—breast cancer	1.01e-05	0.000142	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IGF1—breast cancer	1.01e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—AKT2—breast cancer	1.01e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—EGFR—breast cancer	1e-05	0.00014	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EGFR—breast cancer	9.98e-06	0.00014	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IGF1—breast cancer	9.86e-06	0.000138	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—AKT2—breast cancer	9.85e-06	0.000138	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—EGFR—breast cancer	9.81e-06	0.000137	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CD—breast cancer	9.67e-06	0.000135	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3CA—breast cancer	9.58e-06	0.000134	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SERPINE1—breast cancer	9.57e-06	0.000134	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—COMT—breast cancer	9.49e-06	0.000133	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—KRAS—breast cancer	9.47e-06	0.000133	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CD—breast cancer	9.46e-06	0.000132	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTP1—breast cancer	9.45e-06	0.000132	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—KRAS—breast cancer	9.43e-06	0.000132	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	9.37e-06	0.000131	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SERPINE1—breast cancer	9.36e-06	0.000131	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HMOX1—breast cancer	9.32e-06	0.00013	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ITPR1—breast cancer	9.3e-06	0.00013	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—KRAS—breast cancer	9.26e-06	0.00013	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOS3—breast cancer	9.13e-06	0.000128	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ABCB1—breast cancer	8.94e-06	0.000125	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOS3—breast cancer	8.94e-06	0.000125	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—TYMS—breast cancer	8.78e-06	0.000123	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CA—breast cancer	8.7e-06	0.000122	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTM1—breast cancer	8.68e-06	0.000122	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOR1—breast cancer	8.68e-06	0.000122	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PLA2G4A—breast cancer	8.68e-06	0.000122	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MDM2—breast cancer	8.67e-06	0.000121	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CA—breast cancer	8.66e-06	0.000121	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—RAF1—breast cancer	8.64e-06	0.000121	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—RELA—breast cancer	8.6e-06	0.00012	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ERBB2—breast cancer	8.54e-06	0.00012	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	8.51e-06	0.000119	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MDM2—breast cancer	8.48e-06	0.000119	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—RAF1—breast cancer	8.45e-06	0.000118	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MTOR—breast cancer	8.43e-06	0.000118	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CB—breast cancer	8.43e-06	0.000118	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—RELA—breast cancer	8.41e-06	0.000118	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TP53—breast cancer	8.38e-06	0.000117	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ERBB2—breast cancer	8.36e-06	0.000117	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GPX1—breast cancer	8.31e-06	0.000116	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CB—breast cancer	8.25e-06	0.000115	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MTOR—breast cancer	8.25e-06	0.000115	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP1A1—breast cancer	8.23e-06	0.000115	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ERCC2—breast cancer	8.16e-06	0.000114	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CXCL8—breast cancer	8.1e-06	0.000113	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—HRAS—breast cancer	8.05e-06	0.000113	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—HRAS—breast cancer	8.01e-06	0.000112	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CXCL8—breast cancer	7.93e-06	0.000111	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDKN1B—breast cancer	7.91e-06	0.000111	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—HRAS—breast cancer	7.87e-06	0.00011	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—AKT1—breast cancer	7.83e-06	0.00011	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CASP3—breast cancer	7.76e-06	0.000109	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL2—breast cancer	7.74e-06	0.000108	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDKN1B—breast cancer	7.74e-06	0.000108	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL6—breast cancer	7.7e-06	0.000108	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MTHFR—breast cancer	7.67e-06	0.000107	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL6—breast cancer	7.67e-06	0.000107	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—AKT1—breast cancer	7.66e-06	0.000107	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CASP3—breast cancer	7.59e-06	0.000106	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL2—breast cancer	7.58e-06	0.000106	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CCND1—breast cancer	7.55e-06	0.000106	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL6—breast cancer	7.54e-06	0.000105	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—JUN—breast cancer	7.53e-06	0.000105	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CTNNB1—breast cancer	7.48e-06	0.000105	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CCND1—breast cancer	7.38e-06	0.000103	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—JUN—breast cancer	7.37e-06	0.000103	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MMP9—breast cancer	7.33e-06	0.000103	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CTNNB1—breast cancer	7.31e-06	0.000102	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDKN1A—breast cancer	7.3e-06	0.000102	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTEN—breast cancer	7.29e-06	0.000102	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MMP9—breast cancer	7.17e-06	0.0001	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDKN1A—breast cancer	7.14e-06	0.0001	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MAPK8—breast cancer	7.13e-06	9.97e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTEN—breast cancer	7.13e-06	9.97e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—AKT1—breast cancer	7.11e-06	9.95e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CAV1—breast cancer	7.08e-06	9.9e-05	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—AKT1—breast cancer	7.07e-06	9.9e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MAPK8—breast cancer	6.97e-06	9.76e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—AKT1—breast cancer	6.95e-06	9.73e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SRC—breast cancer	6.76e-06	9.46e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SRC—breast cancer	6.61e-06	9.25e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—VEGFA—breast cancer	6.58e-06	9.21e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—STAT3—breast cancer	6.52e-06	9.12e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CG—breast cancer	6.45e-06	9.02e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—VEGFA—breast cancer	6.44e-06	9.01e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—STAT3—breast cancer	6.37e-06	8.92e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MAPK3—breast cancer	6.23e-06	8.71e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MAPK3—breast cancer	6.09e-06	8.52e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MYC—breast cancer	6.06e-06	8.47e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TGFB1—breast cancer	6.04e-06	8.45e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MYC—breast cancer	5.92e-06	8.29e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EGFR—breast cancer	5.92e-06	8.29e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TGFB1—breast cancer	5.91e-06	8.27e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EGFR—breast cancer	5.79e-06	8.11e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CD—breast cancer	5.67e-06	7.93e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KRAS—breast cancer	5.59e-06	7.83e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALB—breast cancer	5.59e-06	7.83e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KRAS—breast cancer	5.47e-06	7.66e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NOS3—breast cancer	5.35e-06	7.49e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CA—breast cancer	5.14e-06	7.19e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	5.03e-06	7.04e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TP53—breast cancer	4.97e-06	6.96e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CB—breast cancer	4.94e-06	6.91e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTGS2—breast cancer	4.89e-06	6.85e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TP53—breast cancer	4.86e-06	6.81e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HRAS—breast cancer	4.76e-06	6.66e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HRAS—breast cancer	4.65e-06	6.51e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL6—breast cancer	4.55e-06	6.37e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL6—breast cancer	4.45e-06	6.23e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTEN—breast cancer	4.27e-06	5.97e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—AKT1—breast cancer	4.2e-06	5.88e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—AKT1—breast cancer	4.11e-06	5.75e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CA—breast cancer	3.01e-06	4.21e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AKT1—breast cancer	2.46e-06	3.44e-05	CbGpPWpGaD
